ダウンロード数: 1784
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
60_375.pdf | 953.1 kB | Adobe PDF | 見る/開く |
タイトル: | 筋層非浸潤性膀胱癌に対する再発予防目的Mitomycin C膀胱内注入療法の検討 |
その他のタイトル: | Efficacy of Prophylactic Intravesical Mitomycin C in Patients with Non-Muscle-Invasive Bladder Cancer |
著者: | 大杉, 治之 北村, 悠樹 眞鍋, 由美 増田, 憲彦 伊東, 晴喜 三品 , 睦輝 奥野, 博 |
著者名の別形: | Ohsugi, Haruyuki Kitamura, Yuki Manabe, Yumi Masuda, Norihiko Ito, Haruki Mishina, Mutsuki Okuno, Hiroshi |
キーワード: | Mitomycin C Non-muscle-invasive bladdercancer |
発行日: | Aug-2014 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 60 |
号: | 8 |
開始ページ: | 375 |
終了ページ: | 379 |
抄録: | Intravesical chemotherapy is beneficial for patients with non-muscle-invasive bladder cancer (NMIBC), but optimal drug and regimen selection can be controversial. Mitomycin C (MMC) is commonly used as adjuvant treatment for NMIBC. We retrospectively evaluated the outcomes of 73 patients with NMIBC who were treated with weekly doses of low-dose MMC (20 mg ; n=28 ; 38.4%) orhigh-dose MMC (40 mg ; n=45 ; 61.6%) for6 weeks each, at ourhospital between 2001 and 2010. Treatment outcomes were examined by Kaplan‒Meier analysis with log-rank tests. Patients in the high-dose group showed greater recurrent-free survival (61.3%) at 2 years than did patients in the low-dose group (32.6%) (P<0.05). We also found that a single early dose of pirarubicin following transurethral resection of bladder tumor improved MMC efficacy in the high-dose group. The high-dose group had a somewhat higher incidence of dysuria, urinary frequency and drug eruption, but the difference was not significant. |
著作権等: | 許諾条件により本文は2015/09/01に公開 |
URI: | http://hdl.handle.net/2433/189543 |
PubMed ID: | 25179987 |
出現コレクション: | Vol. 60 No. 8 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。